The first domestically produced anti-new crown oral drug has been delivered to Hainan and other places, and more new drugs are being developed

Azvudine, the first domestically produced oral drug for COVID-19, arrived in Hainan and other places at a price of 270 yuan per bottle. The drug was originally an anti-HIV drug with independent intellectual property rights. HIV is an RNA virus. At the beginning of the epidemic, the drug was designated as an anti-new crown screening drug, and finally stood out as the first domestic small-molecule anti-new coronavirus oral drug with expanded indications.

At present, domestic anti-new crown drugs are still under continuous research and development. They are divided into three research and development paths, namely blocking virus entry into cells, inhibiting virus replication, and regulating human immune system. These three paths just cover For the entire process of the virus in the body, as long as it cannot enter the cell, it cannot replicate. If the replication is inhibited in the cell, the number of the virus can be reduced, and the replicated virus can be cleared by the immune system antibodies and cells, which can also speed up the virus turning negative. At present, there are three routes in China to deploy new drug research and development.

With the advancement of new coronavirus drug research and development, more anti-new crown drugs will be launched in the future, and epidemic prevention and control will enter a new stage, but the dynamic clearing strategy will not be relaxed from beginning to end until The global epidemic has entered a stage of low mortality and low infection rates.